Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review

Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Acadia Pharmaceuticals Inc (Acadia) discovers, develops, and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA-approved drug for the treatment of Parkinson’s disease psychosis. It's pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, Major Depressive Disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has operational presence in Denmark, Switzerland, and the UK. Acadia is headquartered in San Diego, California, the US.

Acadia Pharmaceuticals Inc Key Recent Developments

Feb 27,2023: Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
Jan 09,2023: Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
Nov 02,2022: Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
Oct 27,2022: Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Acadia Pharmaceuticals Inc - Key Facts
Acadia Pharmaceuticals Inc - Key Employees
Acadia Pharmaceuticals Inc - Key Employee Biographies
Acadia Pharmaceuticals Inc - Major Products and Services
Acadia Pharmaceuticals Inc - History
Acadia Pharmaceuticals Inc - Company Statement
Acadia Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Acadia Pharmaceuticals Inc - Business Description
R&D Overview
Acadia Pharmaceuticals Inc - Corporate Strategy
Acadia Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Acadia Pharmaceuticals Inc - Strengths
Acadia Pharmaceuticals Inc - Weaknesses
Acadia Pharmaceuticals Inc - Opportunities
Acadia Pharmaceuticals Inc - Threats
Acadia Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Acadia Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 27, 2023: Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
Jan 09, 2023: Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
Nov 02, 2022: Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
Oct 27, 2022: Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
Oct 21, 2022: Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Oct 13, 2022: Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
Sep 28, 2022: Henry Ford Health, Acadia Healthcare break ground on behavioural health hospital in Michigan
Sep 01, 2022: Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 08, 2022: Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
May 03, 2022: Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Acadia Pharmaceuticals Inc, Key Facts
Acadia Pharmaceuticals Inc, Key Employees
Acadia Pharmaceuticals Inc, Key Employee Biographies
Acadia Pharmaceuticals Inc, Major Products and Services
Acadia Pharmaceuticals Inc, History
Acadia Pharmaceuticals Inc, Other Locations
Acadia Pharmaceuticals Inc, Subsidiaries
Acadia Pharmaceuticals Inc, Key Competitors
Acadia Pharmaceuticals Inc, Ratios based on current share price
Acadia Pharmaceuticals Inc, Annual Ratios
Acadia Pharmaceuticals Inc, Annual Ratios (Cont...1)
Acadia Pharmaceuticals Inc, Interim Ratios
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Acadia Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Acadia Pharmaceuticals Inc, Performance Chart (2018 - 2022)
Acadia Pharmaceuticals Inc, Ratio Charts
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings